Matuzumab Short-Term Therapy in Experimental Pancreatic Cancer: Prolonged Antitumor Activity in Combination with Gemcitabine
Purpose: The epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown promising results. We wanted to evaluate matuzumab (EMD72000), a fully humanized ErbB-1–specific monoclonal antibody in combination with gemcitabine in experimental pancreat...
Saved in:
Published in | Clinical cancer research Vol. 14; no. 17; pp. 5426 - 5436 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
01.09.2008
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose: The epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown promising
results. We wanted to evaluate matuzumab (EMD72000), a fully humanized ErbB-1–specific monoclonal antibody in combination
with gemcitabine in experimental pancreatic cancer.
Experimental Design: Using the human pancreatic cancer cell line L3.6pl, we investigated matuzumab in vitro and in vivo . ErbB-1 phosphorylation and downstream pathway activation were evaluated by Western blot. Proliferation and migration assays
and fluorescence-activated cell sorting analysis were done. For in vivo studies, we used an orthotopic nude mice model in which 40 mg/kg of matuzumab ± 100 mg/kg of gemcitabine were administered
twice weekly. Different treatment durations (7, 14, 21, and 25 days) and varying time points of treatment initiation (days
8, 15, 22, and 29) were evaluated. Ki67, CD31, and phosphorylated p44/42 mitogen-activated protein kinase (MAPK) immunohistochemistry
were done.
Results: ErbB-1 phosphorylation and downstream MAPK and AKT signaling were significantly reduced by matuzumab. Matuzumab significantly
inhibited proliferation and migration in vitro , and induced tumor cell apoptosis in a dose-dependant manner. Matuzumab therapy significantly lowered tumor volume in vivo , reduced lymph node and liver metastases, and decreased microvessel density and tumor cell proliferation. These effects were
significantly enhanced when gemcitabine was added. A significant and prolonged antitumor activity was even evident with short-term
therapy (7 days) and with a late onset of therapy (day 22 after tumor cell injection).
Conclusions: Matuzumab is an effective agent with long-lasting antiproliferative, proapoptotic, antiangiogenic, and antimetastatic activity
in human pancreatic cancer models. These effects might be potentiated by gemcitabine. |
---|---|
AbstractList | PURPOSEThe epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown promising results. We wanted to evaluate matuzumab (EMD72000), a fully humanized ErbB-1-specific monoclonal antibody in combination with gemcitabine in experimental pancreatic cancer.EXPERIMENTAL DESIGNUsing the human pancreatic cancer cell line L3.6pl, we investigated matuzumab in vitro and in vivo. ErbB-1 phosphorylation and downstream pathway activation were evaluated by Western blot. Proliferation and migration assays and fluorescence-activated cell sorting analysis were done. For in vivo studies, we used an orthotopic nude mice model in which 40 mg/kg of matuzumab+/-100 mg/kg of gemcitabine were administered twice weekly. Different treatment durations (7, 14, 21, and 25 days) and varying time points of treatment initiation (days 8, 15, 22, and 29) were evaluated. Ki67, CD31, and phosphorylated p44/42 mitogen-activated protein kinase (MAPK) immunohistochemistry were done.RESULTSErbB-1 phosphorylation and downstream MAPK and AKT signaling were significantly reduced by matuzumab. Matuzumab significantly inhibited proliferation and migration in vitro, and induced tumor cell apoptosis in a dose-dependant manner. Matuzumab therapy significantly lowered tumor volume in vivo, reduced lymph node and liver metastases, and decreased microvessel density and tumor cell proliferation. These effects were significantly enhanced when gemcitabine was added. A significant and prolonged antitumor activity was even evident with short-term therapy (7 days) and with a late onset of therapy (day 22 after tumor cell injection).CONCLUSIONSMatuzumab is an effective agent with long-lasting antiproliferative, proapoptotic, antiangiogenic, and antimetastatic activity in human pancreatic cancer models. These effects might be potentiated by gemcitabine. Purpose: The epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown promising results. We wanted to evaluate matuzumab (EMD72000), a fully humanized ErbB-1–specific monoclonal antibody in combination with gemcitabine in experimental pancreatic cancer. Experimental Design: Using the human pancreatic cancer cell line L3.6pl, we investigated matuzumab in vitro and in vivo . ErbB-1 phosphorylation and downstream pathway activation were evaluated by Western blot. Proliferation and migration assays and fluorescence-activated cell sorting analysis were done. For in vivo studies, we used an orthotopic nude mice model in which 40 mg/kg of matuzumab ± 100 mg/kg of gemcitabine were administered twice weekly. Different treatment durations (7, 14, 21, and 25 days) and varying time points of treatment initiation (days 8, 15, 22, and 29) were evaluated. Ki67, CD31, and phosphorylated p44/42 mitogen-activated protein kinase (MAPK) immunohistochemistry were done. Results: ErbB-1 phosphorylation and downstream MAPK and AKT signaling were significantly reduced by matuzumab. Matuzumab significantly inhibited proliferation and migration in vitro , and induced tumor cell apoptosis in a dose-dependant manner. Matuzumab therapy significantly lowered tumor volume in vivo , reduced lymph node and liver metastases, and decreased microvessel density and tumor cell proliferation. These effects were significantly enhanced when gemcitabine was added. A significant and prolonged antitumor activity was even evident with short-term therapy (7 days) and with a late onset of therapy (day 22 after tumor cell injection). Conclusions: Matuzumab is an effective agent with long-lasting antiproliferative, proapoptotic, antiangiogenic, and antimetastatic activity in human pancreatic cancer models. These effects might be potentiated by gemcitabine. Abstract Purpose: The epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown promising results. We wanted to evaluate matuzumab (EMD72000), a fully humanized ErbB-1–specific monoclonal antibody in combination with gemcitabine in experimental pancreatic cancer. Experimental Design: Using the human pancreatic cancer cell line L3.6pl, we investigated matuzumab in vitro and in vivo. ErbB-1 phosphorylation and downstream pathway activation were evaluated by Western blot. Proliferation and migration assays and fluorescence-activated cell sorting analysis were done. For in vivo studies, we used an orthotopic nude mice model in which 40 mg/kg of matuzumab ± 100 mg/kg of gemcitabine were administered twice weekly. Different treatment durations (7, 14, 21, and 25 days) and varying time points of treatment initiation (days 8, 15, 22, and 29) were evaluated. Ki67, CD31, and phosphorylated p44/42 mitogen-activated protein kinase (MAPK) immunohistochemistry were done. Results: ErbB-1 phosphorylation and downstream MAPK and AKT signaling were significantly reduced by matuzumab. Matuzumab significantly inhibited proliferation and migration in vitro, and induced tumor cell apoptosis in a dose-dependant manner. Matuzumab therapy significantly lowered tumor volume in vivo, reduced lymph node and liver metastases, and decreased microvessel density and tumor cell proliferation. These effects were significantly enhanced when gemcitabine was added. A significant and prolonged antitumor activity was even evident with short-term therapy (7 days) and with a late onset of therapy (day 22 after tumor cell injection). Conclusions: Matuzumab is an effective agent with long-lasting antiproliferative, proapoptotic, antiangiogenic, and antimetastatic activity in human pancreatic cancer models. These effects might be potentiated by gemcitabine. The epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown promising results. We wanted to evaluate matuzumab (EMD72000), a fully humanized ErbB-1-specific monoclonal antibody in combination with gemcitabine in experimental pancreatic cancer. Using the human pancreatic cancer cell line L3.6pl, we investigated matuzumab in vitro and in vivo. ErbB-1 phosphorylation and downstream pathway activation were evaluated by Western blot. Proliferation and migration assays and fluorescence-activated cell sorting analysis were done. For in vivo studies, we used an orthotopic nude mice model in which 40 mg/kg of matuzumab+/-100 mg/kg of gemcitabine were administered twice weekly. Different treatment durations (7, 14, 21, and 25 days) and varying time points of treatment initiation (days 8, 15, 22, and 29) were evaluated. Ki67, CD31, and phosphorylated p44/42 mitogen-activated protein kinase (MAPK) immunohistochemistry were done. ErbB-1 phosphorylation and downstream MAPK and AKT signaling were significantly reduced by matuzumab. Matuzumab significantly inhibited proliferation and migration in vitro, and induced tumor cell apoptosis in a dose-dependant manner. Matuzumab therapy significantly lowered tumor volume in vivo, reduced lymph node and liver metastases, and decreased microvessel density and tumor cell proliferation. These effects were significantly enhanced when gemcitabine was added. A significant and prolonged antitumor activity was even evident with short-term therapy (7 days) and with a late onset of therapy (day 22 after tumor cell injection). Matuzumab is an effective agent with long-lasting antiproliferative, proapoptotic, antiangiogenic, and antimetastatic activity in human pancreatic cancer models. These effects might be potentiated by gemcitabine. |
Author | Christiane J. Bruns Martin E. Eichhorn Axel Kleespies Christiane Amendt Karl-Walter Jauch Ivan Ischenko Hendrik Seeliger Ole Mantell |
Author_xml | – sequence: 1 givenname: Axel surname: KLEESPIES fullname: KLEESPIES, Axel organization: Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilian-University, Munich, Germany – sequence: 2 givenname: Ivan surname: ISCHENKO fullname: ISCHENKO, Ivan organization: Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilian-University, Munich, Germany – sequence: 3 givenname: Martin E surname: EICHHORN fullname: EICHHORN, Martin E organization: Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilian-University, Munich, Germany – sequence: 4 givenname: Hendrik surname: SEELIGER fullname: SEELIGER, Hendrik organization: Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilian-University, Munich, Germany – sequence: 5 givenname: Christiane surname: AMENDT fullname: AMENDT, Christiane organization: Merck Serono Research, Merck KGaA, Darmstadt, Germany – sequence: 6 givenname: Ole surname: MANTELL fullname: MANTELL, Ole organization: Department of Surgery, University of Regensburg, Regensburg, Germany – sequence: 7 givenname: Karl-Walter surname: JAUCH fullname: JAUCH, Karl-Walter organization: Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilian-University, Munich, Germany – sequence: 8 givenname: Christiane J surname: BRUNS fullname: BRUNS, Christiane J organization: Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilian-University, Munich, Germany |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20971299$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18765534$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkE1v1DAQhi1URD_gJ4B8AamHFH_GG26rqBSkIipYzpbjnTRGib3YDqUVPx6nu8BpRqPnndE8p-jIBw8IvaTkglK5ekuJWlVEcHbRtl8qoirJhHyCTqiUquKslkel_8sco9OUvhNCBSXiGTqmK1VLycUJ-v3J5PlhnkyHvw4h5moDccKbAaLZ3WPn8eWvHUQ3gc9mxDfG2wgmO4vb0kJ8h29iGIO_hS1e--zyPIWI1za7ny4_5tswdc6XSPD4zuUBX8FkXTZlCM_R096MCV4c6hn69v5y036orj9ffWzX15XliuaqJ2BqILCFbsU4A84sM5x1vYBa8EaJnsKKbIlgTWfqBsqTRhLe9WBJ3SvFz9Cb_d5dDD9mSFlPLlkYR-MhzEnXjWhKYAHlHrQxpBSh17vyu4n3mhK9aNeLUr0o1UW7Jkov2kvu1eHA3E2w_Z86eC7A6wNgkjVjH4s9l_5xjDSKsqYp3PmeG9ztcOciaPvoOUICE-2gqdC0HBWs5n8AEZqdKg |
CODEN | CCREF4 |
CitedBy_id | crossref_primary_10_1016_j_ctrv_2018_08_002 crossref_primary_10_1016_j_addr_2009_11_007 crossref_primary_10_1634_theoncologist_2008_0153 crossref_primary_10_1016_j_febslet_2008_11_010 crossref_primary_10_1097_MPA_0b013e31827aedef |
Cites_doi | 10.3322/canjclin.52.1.23 10.1038/sj.onc.1202367 10.1200/JCO.2005.06.023 10.1016/S0093-7754(02)70088-2 10.1158/1078-0432.CCR-06-0833 10.1002/hep.510270409 10.1002/jcb.10287 10.1016/S0140-6736(04)15841-8 10.1016/S1470-2045(04)01565-7 10.1002/ijc.20696 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S 10.1016/S0360-3016(02)03788-4 10.2174/1389450053765842 10.1200/JCO.2004.05.114 10.1016/j.cellsig.2006.01.011 10.1158/1078-0432.CCR-03-0488 10.1593/neo.05304 10.1002/path.1711660103 10.1038/sj.bjc.6603083 10.1200/JCO.2004.12.040 10.1002/1097-0142(20000701)89:1<74::AID-CNCR11>3.0.CO;2-K 10.1016/j.ygyno.2006.10.019 10.1016/j.drup.2007.03.003 10.1038/sj.neo.7900005 10.1002/cncr.22036 10.1002/bjs.1800820137 10.1016/j.jss.2006.06.031 10.3748/wjg.v12.i43.6973 10.1038/sj.onc.1210129 10.1093/annonc/mdl042 10.1172/JCI116001 10.1007/s10555-005-6192-2 10.1016/j.drup.2006.02.002 10.1177/107327480401100205 |
ContentType | Journal Article |
Copyright | 2009 INIST-CNRS |
Copyright_xml | – notice: 2009 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1158/1078-0432.CCR-07-5245 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1557-3265 |
EndPage | 5436 |
ExternalDocumentID | 10_1158_1078_0432_CCR_07_5245 18765534 20971299 14_17_5426 |
Genre | Journal Article |
GroupedDBID | - 08R 29B 2WC 34G 39C 3O- 4H- 53G 55 5GY 5RE 5VS AAPBV ABFLS ABOCM ACIWK ACPRK ADACO ADBBV ADBIT AENEX AETEA AFFNX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL C1A CS3 DIK DU5 E3Z EBS EJD F5P FH7 FRP GX1 H13 H~9 IH2 KQ8 L7B LSO MVM O0- OHT OK1 P0W P2P RCR RHF RHI RNS SJN UDS VH1 W2D WOQ X7M XFK XJT ZA5 ZCG --- .55 .GJ 18M 1CY 2FS 476 6J9 AAUGY ACGFO ACSVP ADCOW ADNWM AFHIN AFOSN AI. BR6 BTFSW IQODW J5H QTD TR2 W8F WHG YKV ZGI CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c371t-f0ea6e0edeb8232e32c2a32bf4e643974f1e80d0429ba69e410a503bfec06f773 |
ISSN | 1078-0432 |
IngestDate | Fri Aug 16 02:07:36 EDT 2024 Thu Sep 26 15:52:19 EDT 2024 Sat Sep 28 08:34:55 EDT 2024 Sun Oct 29 17:09:38 EDT 2023 Fri Jan 15 20:06:23 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 17 |
Keywords | Antineoplastic agent Short term Drug combination Gemcitabine Monoclonal antibody Malignant tumor Biological activity Matuzumab Treatment Antimetabolic Pancreas cancer Pyrimidine derivatives Digestive diseases Fluorine Organic compounds Pyrimidine nucleoside Cancer Pancreatic disease Prolonged |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c371t-f0ea6e0edeb8232e32c2a32bf4e643974f1e80d0429ba69e410a503bfec06f773 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 18765534 |
PQID | 69495037 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_69495037 crossref_primary_10_1158_1078_0432_CCR_07_5245 pubmed_primary_18765534 pascalfrancis_primary_20971299 highwire_cancerresearch_14_17_5426 |
ProviderPackageCode | RHF RHI |
PublicationCentury | 2000 |
PublicationDate | 2008-09-01 |
PublicationDateYYYYMMDD | 2008-09-01 |
PublicationDate_xml | – month: 09 year: 2008 text: 2008-09-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Philadelphia, PA |
PublicationPlace_xml | – name: Philadelphia, PA – name: United States |
PublicationTitle | Clinical cancer research |
PublicationTitleAlternate | Clin Cancer Res |
PublicationYear | 2008 |
Publisher | American Association for Cancer Research |
Publisher_xml | – name: American Association for Cancer Research |
References | 2022061021433761100_B1 2022061021433761100_B2 2022061021433761100_B3 2022061021433761100_B19 2022061021433761100_B16 2022061021433761100_B38 2022061021433761100_B15 2022061021433761100_B37 2022061021433761100_B18 2022061021433761100_B17 2022061021433761100_B39 2022061021433761100_B12 2022061021433761100_B34 2022061021433761100_B11 2022061021433761100_B33 2022061021433761100_B14 2022061021433761100_B36 2022061021433761100_B13 2022061021433761100_B35 2022061021433761100_B30 2022061021433761100_B10 2022061021433761100_B32 2022061021433761100_B31 2022061021433761100_B27 2022061021433761100_B26 2022061021433761100_B29 2022061021433761100_B28 2022061021433761100_B4 2022061021433761100_B23 2022061021433761100_B5 2022061021433761100_B22 2022061021433761100_B44 2022061021433761100_B6 2022061021433761100_B25 2022061021433761100_B7 2022061021433761100_B24 2022061021433761100_B8 2022061021433761100_B41 2022061021433761100_B9 2022061021433761100_B40 2022061021433761100_B21 2022061021433761100_B43 2022061021433761100_B20 2022061021433761100_B42 |
References_xml | – ident: 2022061021433761100_B2 doi: 10.3322/canjclin.52.1.23 – ident: 2022061021433761100_B18 – ident: 2022061021433761100_B32 doi: 10.1038/sj.onc.1202367 – ident: 2022061021433761100_B43 – ident: 2022061021433761100_B5 doi: 10.1200/JCO.2005.06.023 – ident: 2022061021433761100_B13 doi: 10.1016/S0093-7754(02)70088-2 – ident: 2022061021433761100_B14 – ident: 2022061021433761100_B42 doi: 10.1158/1078-0432.CCR-06-0833 – ident: 2022061021433761100_B16 – ident: 2022061021433761100_B33 doi: 10.1002/hep.510270409 – ident: 2022061021433761100_B37 doi: 10.1002/jcb.10287 – ident: 2022061021433761100_B6 doi: 10.1016/S0140-6736(04)15841-8 – ident: 2022061021433761100_B10 doi: 10.1016/S1470-2045(04)01565-7 – ident: 2022061021433761100_B17 doi: 10.1002/ijc.20696 – ident: 2022061021433761100_B35 doi: 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S – ident: 2022061021433761100_B29 doi: 10.1016/S0360-3016(02)03788-4 – ident: 2022061021433761100_B15 doi: 10.2174/1389450053765842 – ident: 2022061021433761100_B21 doi: 10.1200/JCO.2004.05.114 – ident: 2022061021433761100_B34 – ident: 2022061021433761100_B11 – ident: 2022061021433761100_B36 doi: 10.1016/j.cellsig.2006.01.011 – ident: 2022061021433761100_B39 doi: 10.1158/1078-0432.CCR-03-0488 – ident: 2022061021433761100_B25 – ident: 2022061021433761100_B24 doi: 10.1593/neo.05304 – ident: 2022061021433761100_B12 doi: 10.1002/path.1711660103 – ident: 2022061021433761100_B22 doi: 10.1038/sj.bjc.6603083 – ident: 2022061021433761100_B30 doi: 10.1200/JCO.2004.12.040 – ident: 2022061021433761100_B28 doi: 10.1002/1097-0142(20000701)89:1<74::AID-CNCR11>3.0.CO;2-K – ident: 2022061021433761100_B20 doi: 10.1016/j.ygyno.2006.10.019 – ident: 2022061021433761100_B38 – ident: 2022061021433761100_B9 doi: 10.1016/j.drup.2007.03.003 – ident: 2022061021433761100_B23 doi: 10.1038/sj.neo.7900005 – ident: 2022061021433761100_B3 doi: 10.1002/cncr.22036 – ident: 2022061021433761100_B1 doi: 10.1002/bjs.1800820137 – ident: 2022061021433761100_B31 doi: 10.1016/j.jss.2006.06.031 – ident: 2022061021433761100_B4 doi: 10.3748/wjg.v12.i43.6973 – ident: 2022061021433761100_B40 doi: 10.1038/sj.onc.1210129 – ident: 2022061021433761100_B19 doi: 10.1093/annonc/mdl042 – ident: 2022061021433761100_B26 – ident: 2022061021433761100_B27 doi: 10.1172/JCI116001 – ident: 2022061021433761100_B41 – ident: 2022061021433761100_B44 doi: 10.1007/s10555-005-6192-2 – ident: 2022061021433761100_B8 doi: 10.1016/j.drup.2006.02.002 – ident: 2022061021433761100_B7 doi: 10.1177/107327480401100205 |
SSID | ssj0014104 |
Score | 2.02147 |
Snippet | Purpose: The epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown promising
results. We wanted to... The epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown promising results. We wanted to evaluate... Abstract Purpose: The epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown promising results. We... PURPOSEThe epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown promising results. We wanted to... |
SourceID | proquest crossref pubmed pascalfrancis highwire |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 5426 |
SubjectTerms | AKT Animals Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis - drug effects Biological and medical sciences Cell Movement - drug effects Cell Proliferation - drug effects Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives EGFR EMD72000 Gastroenterology. Liver. Pancreas. Abdomen Humans Liver. Biliary tract. Portal circulation. Exocrine pancreas MAPK Medical sciences Mice monoclonal antibody Neoplasm Metastasis - prevention & control Neovascularization, Pathologic - drug therapy Pancreatic Neoplasms - drug therapy Pharmacology. Drug treatments targeted therapy Tumor Cells, Cultured Tumors Xenograft Model Antitumor Assays |
Title | Matuzumab Short-Term Therapy in Experimental Pancreatic Cancer: Prolonged Antitumor Activity in Combination with Gemcitabine |
URI | http://clincancerres.aacrjournals.org/content/14/17/5426.abstract https://www.ncbi.nlm.nih.gov/pubmed/18765534 https://search.proquest.com/docview/69495037 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF6FIiFeEHfNUVaIt8jBx64P3qpQlFKFB2ilvq3W9riNmjhV4yBU8S_4w8wevkQrAS9WZDvr9X7fjmdmZ2YJeZfiJ1omgXSzJJIuY2XpqqpzbonmRxbGXhnq5YL5l2h2wj6f8tPR6FcvamlbZ5P8-sa8kv9BFc8hripL9h-QbRvFE_gb8cUjIozHv8J4Luvt9XYls_HmHNVoV4nZscmo0ul8g_L9OO2NhpirSK8c9P6QKD-X6-oMVMFWFTSwUjGVud1RwoSoo-lsSKJdtmewyhe1zJrl-KbIQZNgaZoe2xpCra_5aAlqTd_IpP0fsOwoiaypLrTD9vB7R9WDRX6O71TZfKIa-9LmTHwDFUdtuDaDqrhaXAycF0kbndXIW08V-GXhUCCzPvHinnjlzKTX_yn3eaJdELa1yXT6VTlgeWBqVfa4cLnSZPDxK8C59aMOC243l-6Qu0GccmXRfzw8apemmK_3pGyfZdPCsAfvb3y-KktrWxzqPk09ahWOKzcIUWm2Urnd1tE6z_FD8sAaK3TfMO8RGUH1mNyb23CMJ-RnS0DaEZBaAtJFRfsEpB0BqWHJB9rSj7b0ow391P979KOKfrRHv6fk5NPB8XTm2u083DyM_dotPZAReFBAlqAeD2GQBzIMspKBVotZ6UPiFUpDymSUAg605F6YlZB7URnH4TOyU60r2CU0KTiXSe6HUZQygCwFYEWYFpCzIsE2HTJpBlpcmqotQlu7PBEKJKFAEgiS8GKhQHLI2wYOYYagmSdoGwsfb0LmOWRvAFTbdKAKsaFe55A3DXICpbRaepMVrLcbgd1M8V1ihzw3gHbdstx4ceuVl-R-N3VekZ36aguvUROusz3NzN8rWrUc |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Matuzumab+short-term+therapy+in+experimental+pancreatic+cancer%3A+prolonged+antitumor+activity+in+combination+with+gemcitabine&rft.jtitle=Clinical+cancer+research&rft.au=Kleespies%2C+Axel&rft.au=Ischenko%2C+Ivan&rft.au=Eichhorn%2C+Martin+E&rft.au=Seeliger%2C+Hendrik&rft.date=2008-09-01&rft.issn=1078-0432&rft.volume=14&rft.issue=17&rft.spage=5426&rft_id=info:doi/10.1158%2F1078-0432.CCR-07-5245&rft_id=info%3Apmid%2F18765534&rft.externalDocID=18765534 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |